Smokers' preferences for medicinal nicotine vs smokeless tobacco

American Journal of Health Behavior

Volumn 31, Issue 5, 2007, Pages 462-472

  Shiffman, Saul ^a,b   Gitchell, Joe ^a   Rohay, Jeffrey M ^a   Hellebusch, Stephen J ^c   Kemper, Katherine E ^d  

^a PINNEY ASSOCIATES   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Hellebusch Research and Consulting Inc   (United States)

^d NONE

Author keywords

Harm reduction; Medicinal nicotine; Nicotine replacement therapy; Smokeless tobacco; Smoking

Indexed keywords

EID: 34548567029     PISSN: 10873244     EISSN: None     Source Type: Journal    
DOI: 10.5993/AJHB.31.5.2     Document Type: Article

References (38)

1. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control. 2001;10(2):189-195.
2. Kozlowski LT, O'Connor RJ, Sweeney CT. Cigarette Design. In: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Smoking and Tobacco Control Monograph No. 13. NIH Pub. No. 02-5074 Bethesda, MD., October, 2001.
3. Burton SL, Gitchell JG, Shiffman S. Use of FDA-approved Pharmacologic Treatments for Tobacco Dependence - United States, 1984-1998. Morb Mortal Wkly Rep. 2000;49(29):665-668.
4. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. 2000.
5. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996;109(2):438-445.
6. Bolliger CT, Zellweger JP, Danielsson T, et al. Smoking reduction with oral nicotine inhalers: double blind, randomized clinical trial of efficacy and safety. BMJ. 2000;321(7257):329-333.
7. Wennike P, Danielsson T, Landfeldt B, et al. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98(10):1395-1402.
8. Shiffman S, Gitchell JG, Warner KE, et al. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res. 2002;2(Suppl 4):S113-S129.
9. Kozlowski LT. Harm reduction, public health, and human rights: smokers have a right to be informed of significant harm reduction options. Nicotine Tob Res. 2002;2(Suppl 4):S55-S60.
10. Bates C, Fagerstrom K, Jarvis MJ, et al. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tob Control. 2003;12(4):360-367.
11. McNeill A. Harm reduction. BMJ. 2004;328(7444):885-887.
12. US Department of Health and Human Services. The Health Consequences of Smoking. A report of the Surgeon General, 2004. Rockville, Maryland: Centers for Disease Control, Office on Smoking and Health, 2004. (Stock Number 0-16-051576-2)
13. Royal College of Physicians of London. Nicotine Addiction in Britain: A report of the Tobacco Advisory Group of The Royal College of Physicians. London. Royal College of Physicians of London. 2000.
14. The International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 89: Smokeless Tobacco and Some Tobacco Specific Nitrosamines. Lyon: IARC Press 2004.
15. Hatsukami DK, Lemmonds C, Zhang Y, et al. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. J Natl Cancer Inst. 2004;96(11):844-852.
16. Kozlowski LT, Strasser AA, Giovino GA, et al. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control. 2001;10(3):201-203.
17. Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control. 2003;12(4):349-359.
18. Hall WD. The prospects for tobacco harm reduction. Int. J. Drug Policy. 2005;16:139-142
19. Substance Abuse and Mental Health Services Administration. Results from the 2002 National Survey on Drug Use and Health. Detailed Tables (online). Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2003. Available at: http://www.oas.samhsa.gov/nhsda/ 2k2nsduh/Sect2peTabs35to39.pdf. Accessed August 28, 2006.
20. US Food and Drug Administration. Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents. 61 Fed Reg 44,396, 44,887. Aug 28 1996.
21. Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med. 2005;28(1):119-122
22. Shiffman S, Hughes JR, Pillitteri JL, Burton SL. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tob Control. 2003;12(3):310-316.
23. Shiffman S, Hughes JR, Di Marino ME, Sweeney CT. Patterns of over-the-counter nicotine gum use: persistent use and concurrent smoking. Addiction. 2003;98(12):1747-1753.
24. SurveySampling.com [homepage on the Internet]. Copyright 2005 Survey Sampling Inc. [cited on 6/28/2005] Available at: http://www.surveysampling.com. Accessed August 28, 2006.
25. McCarty C. Differences in Response rates using most recent versus final dispositions in telephone surveys. Pub Opinion Q. 2003;67:396-406.
26. Rosner B. Fundamentals of Biostatistics, 2nd Edition. Duxberry Press, Boston, MA. 1986.
27. DiClemente CC, Prochaska JO, Fairhurst SK, et al. The processes of smoking cessation: An analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psych. 1991;59:295-304.
28. Bansal MA, Cummings KM, Hyland A, Giovino GA. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Nicotine Tob Res. 2004;6(Suppl 3):S303-S310.
29. Tomar SL, Loree M. Errors in analyzing associations between use of smokeless tobacco and cigarettes. Addiction. 2004;99(2):260-262; author reply 262-264.
30. Tomar SL. Smokeless tobacco use is a significant predictor of smoking when appropriately modeled. Nicotine Tob Res. 2003;5(4):571-573.
31. Tomar SL. Is use of smokeless tobacco a risk factor for cigarette smoking? The U.S. experience. Nicotine Tob Res. 2003;5(4):561-569.
32. O'Connor RJ, Flaherty BP, Edwards BQ, Kozlowski LT. Regular smokeless tobacco use is not a reliable predictor of smoking onset when psychosocial predictors are included in the model. Nicotine Tob Res. 2003;5(4):535-543.
33. O'Connor RJ, Kozlowski LT, Flaherty BP, Edwards BQ. Most smokeless tobacco use does not cause cigarette smoking: results from the 2000 National Household Survey on Drug Abuse. Addict Behav. 2005;30(2):325-336.
34. CommitLozenge.com (online). Copyright 2002 GlaxoSmithKline Inc. [cited on 6/7/2005] Available at: http://www.commitlozenge.com. Accessed August 28, 2006.
35. GoAriva.com [homepage on the Internet]. Star Scientific, [cited on 06/07/2005] Available at: http://www.goariva.com. Accessed August 28, 2006.
36. Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J. 1998;53(Suppl):75-114.
37. Fant RV, Henningfield JE, Nelson RA, Pickworth WB. Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tobacco Control 1999;8:387-392.
38. Benowitz NL, Porchet H, Sheiner L, Jacob P 3rd. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988;44(1):23-28.